Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 17 studies | 26% ± 9% | |
| peripheral blood | 16 studies | 34% ± 10% | |
| brain | 12 studies | 33% ± 16% | |
| intestine | 8 studies | 24% ± 10% | |
| kidney | 7 studies | 24% ± 8% | |
| eye | 6 studies | 31% ± 13% | |
| pancreas | 4 studies | 41% ± 16% | |
| bone marrow | 4 studies | 30% ± 14% | |
| lymph node | 4 studies | 30% ± 3% | |
| breast | 4 studies | 20% ± 3% | |
| liver | 4 studies | 38% ± 17% | |
| adipose | 4 studies | 24% ± 4% | |
| uterus | 3 studies | 29% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| bladder | 100% | 12099.14 | 21 / 21 | 100% | 86.29 | 504 / 504 |
| esophagus | 100% | 11908.75 | 1445 / 1445 | 100% | 75.31 | 183 / 183 |
| intestine | 100% | 13592.10 | 966 / 966 | 100% | 76.33 | 527 / 527 |
| pancreas | 100% | 7785.57 | 328 / 328 | 100% | 67.47 | 178 / 178 |
| prostate | 100% | 14592.76 | 245 / 245 | 100% | 79.69 | 502 / 502 |
| skin | 100% | 13273.53 | 1809 / 1809 | 100% | 85.10 | 472 / 472 |
| stomach | 100% | 9964.45 | 359 / 359 | 100% | 72.16 | 286 / 286 |
| uterus | 100% | 14609.76 | 170 / 170 | 100% | 97.76 | 459 / 459 |
| lung | 100% | 12803.63 | 578 / 578 | 100% | 76.11 | 1154 / 1155 |
| breast | 100% | 12811.42 | 459 / 459 | 100% | 76.71 | 1117 / 1118 |
| thymus | 100% | 14733.30 | 653 / 653 | 100% | 77.93 | 604 / 605 |
| liver | 100% | 8015.22 | 226 / 226 | 100% | 46.26 | 405 / 406 |
| kidney | 100% | 10468.75 | 89 / 89 | 100% | 52.04 | 898 / 901 |
| brain | 100% | 10108.16 | 2633 / 2642 | 100% | 87.00 | 705 / 705 |
| ovary | 100% | 13632.77 | 180 / 180 | 100% | 49.35 | 428 / 430 |
| adrenal gland | 100% | 15842.69 | 258 / 258 | 99% | 55.60 | 228 / 230 |
| adipose | 100% | 12279.73 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 11441.15 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 55.52 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 115.64 | 29 / 29 |
| muscle | 100% | 9266.91 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 19452.42 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 93.07 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 44.58 | 1 / 1 |
| heart | 99% | 8289.72 | 852 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 11245.13 | 917 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006355 | Biological process | regulation of DNA-templated transcription |
| GO_0015030 | Cellular component | Cajal body |
| GO_0005730 | Cellular component | nucleolus |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0005516 | Molecular function | calmodulin binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0003712 | Molecular function | transcription coregulator activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0003723 | Molecular function | RNA binding |
| Gene name | EWSR1 |
| Protein name | EWS RNA binding protein 1 (EWS RNA-binding protein variant 6) RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein) EWS RNA binding protein 1 |
| Synonyms | EWS |
| Description | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Accessions | ENST00000629659.2 B0QYJ3 A0A0D9SFL3 H7BY36 B0QYJ7 ENST00000455726.5 ENST00000447973.5 ENST00000415761.5 Q01844 F8WC90 ENST00000333395.11 [Q01844-4] ENST00000332050.10 B0QYJ4 B0QYJ6 ENST00000331029.11 ENST00000437155.6 ENST00000436425.5 ENST00000397938.7 [Q01844-1] C9JGE3 B0QYK0 ENST00000406548.5 [Q01844-3] ENST00000360091.3 B0QYJ5 ENST00000414183.6 [Q01844-5] ENST00000332035.10 [Q01844-6] ENST00000444626.5 |